Posted on: 12 May 2026, source: CHOSUNBIZ U.S. biotech company Fractyl Health is launching the world's first clinical trial of a glucagon-like peptide-1 (GLP-1) gene therapy. As GLP-1 class treatments that mimic the action of the hormone GLP-1, which is naturally secreted in the gut when eating, have emerged, the paradigm for treating diabetes and obesity has changed dramatically. Current GLP-1 treatments on the market are administered as weekly or monthly injections or taken daily, but the industry is focused on the attempt to develop a therapy that induces the body to generate the GLP-1 hormone on its own with a single administration. Fractyl Health said on the 11th (local time) that RJVA-001, its GLP-1 gene therapy under development, received Phase 1/2 clinical trial approval from Dutch regulators. {fastsocialshare}